I did not hear Cooper's comments on CRSPR. I was probably this board's lone apologist for Cooper when he lost his job. Cooper was doing CAR-T work in 2006. He has a career that won him many awards of distinguished contribution. I think Cooper and Rosenberg have been talking to each other for decades. Cooper has degrees in hematology, immunology, and oncology ... his name is included in authorship in ?memory, over 800 papers? But, he ran Ziopharm like a research lab that has unlimited funds and time. His Tariff board COB was enjoying the gravy train, not demanding focus from limited funds. The pivot to CPI combo in Il-12+v without prelim. animal studies was my missed clue.

Sleeping Beauty has minimal PhDs working on its benefits. Around the globe, I estimate a hundred thousand PhDs working on CRSPR variants. In time and with money, as with any problem at hand, with so many resources, eventually CRSPR might emerge as a viable tool for curing human diseases. For the next three years, I will rest on Dr. Deniger's assessment of SB -- simple, economic vectoring. All the best.